European Society of Medical Oncology (ESMO) highlights from the IKCC

19 Sep 2017

Kidney cancer news

17 Apr 2024

Cancer52 manifesto launch

12 Apr 2024

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

9 Apr 2024

CAR T cell immunotherapy shows promise for patients with kidney cancer

9 Apr 2024

Real world data on the use of cabozantinib plus immunotherapy in the second line

25 Mar 2024

How to manage anxiety and depression when you have kidney cancer

12 Mar 2024

Immunotherapy improves survival in kidney cancer patients with brain metastases

8 Mar 2024

Radiotherapy for the management of renal medullary carcinoma

8 Mar 2024

Manchester patient focus group

8 Mar 2024

NICE approves cabozantinib plus nivolumab for advanced kidney cancer

15 Feb 2024

PRISM study highlights possibility of reducing dose of immunotherapy

15 Feb 2024

World-class radiotherapy in the UK

7 Feb 2024

Summary of kidney cancer highlights from ASCO GU 2024

2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

Links

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

European Society of Medical Oncology (ESMO) highlights from the IKCC

European Society of Medical Oncology (ESMO) highlights from the IKCC

Kidney cancer news

Cancer52 manifesto launch

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

CAR T cell immunotherapy shows promise for patients with kidney cancer

Real world data on the use of cabozantinib plus immunotherapy in the second line

How to manage anxiety and depression when you have kidney cancer

Immunotherapy improves survival in kidney cancer patients with brain metastases

Radiotherapy for the management of renal medullary carcinoma

Manchester patient focus group

NICE approves cabozantinib plus nivolumab for advanced kidney cancer

PRISM study highlights possibility of reducing dose of immunotherapy

World-class radiotherapy in the UK

Summary of kidney cancer highlights from ASCO GU 2024

Most used tags

Archives

Address

Helpline

About Action Kidney Cancer

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Policies

Follow

European Society of Medical Oncology (ESMO) highlights from the IKCC

European Society of Medical Oncology (ESMO) highlights from the IKCC

Share this Page:

Share this Page:

Kidney cancer news

Cancer52 manifesto launch

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

CAR T cell immunotherapy shows promise for patients with kidney cancer

Real world data on the use of cabozantinib plus immunotherapy in the second line

How to manage anxiety and depression when you have kidney cancer

Immunotherapy improves survival in kidney cancer patients with brain metastases

Radiotherapy for the management of renal medullary carcinoma

Manchester patient focus group

NICE approves cabozantinib plus nivolumab for advanced kidney cancer

PRISM study highlights possibility of reducing dose of immunotherapy

World-class radiotherapy in the UK

Summary of kidney cancer highlights from ASCO GU 2024

Most used tags

Archives

Address

Helpline

About Action Kidney Cancer

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Policies

Follow